Endo Pharmaceuticals Inc. Company Profile

06:59 EDT 20th September 2017 | BioPortfolio

News Articles [1421 Associated News Articles listed on BioPortfolio]

Endo Pharmaceuticals to remove OPANA from the market

Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of OPANA® ER (oxymorphone hydrochloride extended release) when used as intended, and notes tha...

Alexza Pharmaceuticals (ALXA) and Endo International plc - (ENDP) Head to Head Comparison

Alexza Pharmaceuticals and Endo International plc - are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitabi...

Endo gives way and withdraws opioid painkiller after FDA pressure

Endo Pharmaceuticals has announced it will remove its Opana ER opioid painkiller from the US market, a month after the FDA requested because of the potential for abuse. Dublin-based Endo said that it...

Veloxis, Endo Ventures In Deal For Paladin To Commercialize Envarsus XR

WASHINGTON (dpa-AFX) - Veloxis Pharmaceuticals A/S said that its U.S. subsidiary, Veloxis Pharmaceuticals, Inc., and Endo Ventures Limited have entered into an exclusive license, supply and distri...

Endo Pharmaceuticals to Present at Citi 2012 Global Health Care Conference

CHADDS FORD, Pa., Feb. 13, 2012 /PRNewswire/ -- Endo Pharmaceuticals Holdings (Nasdaq: ENDP) today announced that Alan Levin, executive vice president and chief financial officer, will pr...

In surprise move, FDA asks Endo to pull opioid

Endo Pharmaceuticals' shares spiral down as the FDa takes action to remove the highly abused drug from the market. 

Endo to Present at Bank of America Merrill Lynch 2012 Health Care Conference

CHADDS FORD, Pa., May 4, 2012 /PRNewswire/ -- Endo (Nasdaq: ENDP) today announced that Alan Levin, executive vice president and chief financial officer, will present a corporate overview at the Bank o...

Veloxis Pharmaceuticals A/S: Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada

Investor News no. 04/2017To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 June 2017 Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commer...

Drugs and Medications [287 Associated Drugs and Medications listed on BioPortfolio]

Losartan potassium [Endo Pharmaceuticals Inc. DBA Endo Generic Products]

Losartan Potassium Tablets USP R only

Pramipexole dihydrochloride [Endo Pharmaceuticals Inc. DBA Endo Generic Products]

Pramipexole Dihydrochloride Tablets 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tablets Rx only Prescribing Information

Antitussivehycodan(hydrocodone bitartrate and homatropine methylbromide)tablets and syrupciiir only [Endo Pharmaceuticals Inc.]

ANTITUSSIVEHYCODAN(Hydrocodone Bitartrate and Homatropine Methylbromide)TABLETS AND SYRUPCIIIR only

Pur-wash [Niagara Pharmaceuticals Inc.]


Opana [Endo Pharmaceuticals, Inc]

ENDO PHARMACEUTICALS 003466/September 2006 OPANA (Oxymorphone Hydrochloride) INJECTION 1mg/mL CII Opioid Analgesic Rx only

PubMed Articles [265 Associated PubMed Articles listed on BioPortfolio]

Effectiveness of XP-endo Finisher and XP-endo Finisher R in removing root filling remnants: a micro-CT study.

To evaluate the efficacy of filling material removal from oval-shaped canals after the use of supplementary files (XP-endo Finisher and XP-endo Finisher R) through micro-computed tomographic (micro-CT...

On the Threading of an Inherently Directional Calixarene Wheel with Oriented Ammonium Axles.

The threading of mono-stoppered alkylbenzylammonium axles 7+ and 8+ with the calix[6]-wheel 3 can occurs by both the routes of entering of the macrocycle 3 in the cone conformation: through-the-exo-ri...

Synthesis of Cis,syndiotactic-A-alt-B Copolymers from Enantiomerically Pure Endo-2-Substituted-5,6-Norbornenes.

Cis,syndiotactic A-alt-B copolymers, where A and B are two enantiomerically pure endo-2-substituted-5,6-norbornenes with "opposite" chiralities of the endo-2-substituted-5,6-norbornene skeleton, can b...

Endo-α-mannosidase Catalyzed Transglycosylation.

In order for facilitating the synthesis of oligosaccharides, transglycosylation reactions mediated by glycoside hydrolases have been studied in various contexts. In this study, we examined transglycos...

Exo-exo synergy between Cel6A and Cel7A from Hypocrea jecorina: role of carbohydrate binding module and the endo-lytic character of the enzymes.

Synergy between cellulolytic enzymes is essential in both natural and industrial breakdown of biomass. In addition to synergy between endo-lytic and exo-lytic enzymes, a lesser known but equally consp...

Clinical Trials [251 Associated Clinical Trials listed on BioPortfolio]

The ValenTx Endo Bypass System in Obese Subjects

The purpose of this study is to collect clinical data to support the use of the ValenTx Endo Bypass System to improve weight loss and the resolution of comorbidities in obese subjects.

Comparing Between XP Endo Finisher and Conventional Irrigation Method On Post-Operative Flare Ups In Necrotic Teeth

Comparing the postoperative flare ups and pain after adding the XP Endo Finisher to the final irrigation protocol on necrotic mandibular premolars.

Endo-cuff Assisted Vs. Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening

The study evaluates whether the use of a novel endoscopic cap (the endo-cuff) at the tip of a colonoscope improves the numbers of polyps detected during bowel cancer screening colonoscopy....

Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-Sided Colon Cancer: RCT

Objective: Whether temporary endoscopic decompression by Self-expanding metal stents (SEMS) could allow these patients to undergo successful laparoscopic resection (endo-laparoscopic appro...

A Post-market Study of the Endo GIA™ Reinforced Reload With Tri-Staple™ Technology

A post-market study of the Endo GIA™ Reinforced Reload with Tri-Staple™ Technology.

Companies [1284 Associated Companies listed on BioPortfolio]

Endo Pharmaceuticals

Endo Pharmaceuticals are a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.

Endo Pharmaceuticals Inc.

Endo Pharmaceuticals Holdings Inc.

Endo Pharmaceuticals Holdings

Endo Pharmaceuticals Solutions Inc.

More Information about "Endo Pharmaceuticals Inc." on BioPortfolio

We have published hundreds of Endo Pharmaceuticals Inc. news stories on BioPortfolio along with dozens of Endo Pharmaceuticals Inc. Clinical Trials and PubMed Articles about Endo Pharmaceuticals Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endo Pharmaceuticals Inc. Companies in our database. You can also find out about relevant Endo Pharmaceuticals Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record